Advanced search
Publication Cover
Future Virology Volume 2, 2007 - Issue 1
Submit an article Journal homepage
122
Views
0
CrossRef citations to date
0
Altmetric
Review

Role of Cyclophilin A in HIV Replication

Jörg Vottelera Institute for Clinical & Molecular Virology,University of Erlangen-Nürnberg,Schlossgarten 4,91054Erlangen,Germany Tel.: +49 913 1852 6791; Fax.: +49 913 1852 6182; [email protected]View further author information
,
Victor Wrayb Helmholtz Centre for Infection Research,Department of Structural Biology Inhoffenstraße 7,38124Braunschweig,Germany Tel.: +49 531 6181 7200; Fax.: +49 531 6181 7199; [email protected]View further author information
&
Ulrich SchubertCorrespondence[email protected]
View further author information
Pages 65-78 | Published online: 20 Dec 2006

Bibliography

  • Sorin M , KalpanaGV: Dynamics of virus–host interplay in HIV-1 replication.Curr. HIV Res.4(2), 117–130 (2006).
  • Ott DE : Potential roles of cellular proteins in HIV-1.Rev. Med. Virol.12(6), 359–374 (2002).
  • Ott DE : Cellular proteins in HIV virions.Rev. Med. Virol.7(3), 167–180 (1997).
  • Pornillos O , GarrusJE, SundquistWI: Mechanisms of enveloped RNA virus budding.Trends Cell Biol.12(12), 569–579 (2002).
  • Morita E , SundquistWI: Retrovirus budding.Annu. Rev. Cell Dev. Biol.20, 395–425 (2004).
  • Demirov DG , FreedEO: Retrovirus budding.Virus Res.106(2), 87–102 (2004).
  • Klinger PP , SchubertU: The ubiquitin–proteasome system in HIV replication: potential targets for antiretroviral therapy.Expert Rev. Anti-Infect. Ther.3(1), 61–79 (2005).
  • Martin-Serrano J , ZangT, BieniaszPD: Role of ESCRT-I in retroviral budding.J. Virol.77(8), 4794–4804 (2003).
  • von Schwedler UK , StuchellM, MullerBet al.: The protein network of HIV budding.Cell114(6), 701–713 (2003).
  • Garrus JE , von SchwedlerUK, PornillosOWet al.: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.Cell107(1), 55–65 (2001).
  • Martin-Serrano J , ZangT, BieniaszPD: HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.Nat. Med.7(12), 1313–1319 (2001).
  • Myers EL , AllenJF: Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 Gag polyprotein and results in increased levels of ubiquitinated Gag.J. Virol.76(22), 11226–11235 (2002).
  • VerPlank L , BouamrF, LaGrassaTJet al.: Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).Proc. Natl Acad. Sci. USA98(14), 7724–7729 (2001).
  • Babst M , OdorizziG, EstepaEJ, EmrSD: Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal Trafficking.Traffic1(3), 248–258 (2000).
  • Katzmann DJ , OdorizziG, EmrSD: Receptor downregulation and multivesicular-body sorting.Nat. Rev. Mol. Cell Biol.3(12), 893–905 (2002).
  • Amara A , LittmanDR: After Hrs with HIV.J. Cell Biol.162(3), 371–375 (2003).
  • Schnell JD , HickeL: Non-traditional functions of ubiquitin and ubiquitin-binding proteins.J. Biol. Chem.278(38), 35857–35860 (2003).
  • Perez O , HopeTJ: Cellular restriction factors affecting the early stages of HIV replication.Curr. HIV/AIDS Rep.3(1), 20–25 (2006).
  • Sheehy AM , GaddisNC, ChoiJD, MalimMH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.Nature418(6898), 646–650 (2002).
  • Navarro F , LandauNR: Recent insights into HIV-1 Vif.Curr. Opin. Immunol.16(4), 477–482 (2004).
  • Rose KM , MarinM, KozakSL, KabatD: The viral infectivity factor (Vif) of HIV-1 unveiled.Trends Mol. Med.10(6), 291–297 (2004).
  • Schrofelbauer B , YuQ, LandauNR: New insights into the role of Vif in HIV-1 replication.AIDS Rev.6(1), 34–39 (2004).
  • Vartanian JP , SommerP, Wain-HobsonS: Death and the retrovirus.Trends Mol. Med.9(10), 409–413 (2003).
  • Harris RS , LiddamentMT: Retroviral restriction by APOBEC proteins.Nat. Rev. Immunol.4(11), 868–877 (2004).
  • Cullen BR : Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.J. Virol.80(3), 1067–1076 (2006).
  • Chiu YL , GreeneWC: Multifaceted antiviral actions of APOBEC3 cytidine deaminases.Trends Immunol.27(6), 291–297 (2006).
  • Harris RS , BishopKN, SheehyAMet al.: DNA deamination mediates innate immunity to retroviral infection.Cell113(6), 803–809 (2003).
  • Mangeat B , TurelliP, CaronG, FriedliM, PerrinL, TronoD: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.Nature424(6944), 99–103 (2003).
  • Mehle A , GoncalvesJ, Santa-MartaM, McPikeM, GabuzdaD: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.Genes Dev.18(23), 2861–2866 (2004).
  • Stopak K , de NoronhaC, YonemotoW, GreeneWC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.Mol. Cell12(3), 591–601 (2003).
  • Yu Y , XiaoZ, EhrlichES, YuX, YuXF: Selective assembly of HIV-1 Vif–Cul5–ElonginB–ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.Genes Dev.18(23), 2867–2872 (2004).
  • Yu X , YuY, LiuBet al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif–Cul5–SCF complex.Science302(5647), 1056–1060 (2003).
  • Stremlau M , OwensCM, PerronMJ, KiesslingM, AutissierP, SodroskiJ: The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys.Nature427(6977), 848–853 (2004).
  • Bieniasz PD : Intrinsic immunity: a front-line defense against viral attack.Nat. Immunol.5(11), 1109–1115 (2004).
  • Towers GJ : Control of viral infectivity by tripartite motif proteins.Hum. Gene Ther.16(10), 1125–1132 (2005).
  • Sokolskaja E , LubanJ: Cyclophilin, TRIM5, and innate immunity to HIV-1.Curr. Opin. Microbiol. (2006).
  • Handschumacher RE , HardingMW, RiceJ, DruggeRJ, SpeicherDW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A.Science226(4674), 544–547 (1984).
  • Ivery MT : Immunophilins: switched on protein binding domains?Med. Res. Rev.20(6), 452–484 (2000).
  • Braaten D , LubanJ: Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells.EMBO J.20(6), 1300–1309 (2001).
  • Colgan J , AsmalM, LubanJ: Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability.Genomics68(2), 167–178 (2000).
  • Luban J : Absconding with the chaperone: essential cyclophilin–Gag interaction in HIV-1 virions.Cell87(7), 1157–1159 (1996).
  • Towers GJ , HatziioannouT, CowanS, GoffSP, LubanJ, BieniaszPD: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors.Nat. Med.9(9), 1138–1143 (2003).
  • Sayah DM , SokolskajaE, BerthouxL, LubanJ: Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.Nature430(6999), 569–573 (2004).
  • Luban J , BossoltKL, FrankeEK, KalpanaGV, GoffSP: Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.Cell73(6), 1067–1078 (1993).
  • Franke EK , YuanHE, LubanJ: Specific incorporation of cyclophilin A into HIV-1 virions.Nature372(6504), 359–362 (1994).
  • Thali M , BukovskyA, KondoEet al.: Functional association of cyclophilin A with HIV-1 virions.Nature372(6504), 363–365 (1994).
  • Ott DE , CorenLV, JohnsonDG, Sowder RCII, ArthurLO, HendersonLE: Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.AIDS Res. Hum. Retroviruses11(9), 1003–1006 (1995).
  • Colgan J , YuanHE, FrankeEK, LubanJ: Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.J. Virol.70(7), 4299–4310 (1996).
  • Braaten D , FrankeEK, LubanJ: Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIVCPZGAB but not group O HIV-1 or other primate immunodeficiency viruses.J. Virol.70(7), 4220–4227 (1996).
  • Yoo S , MyszkaDG, YehC, McMurrayM, HillCP, SundquistWI: Molecular recognition in the HIV-1 capsid/cyclophilin A complex.J. Mol. Biol.269(5), 780–795 (1997).
  • Gamble TR , VajdosFF, YooSet al.: Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.Cell87(7), 1285–1294 (1996).
  • Bristow R , ByrneJ, SquirellJet al.: Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24.J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.20(4), 334–336 (1999).
  • Braaten D , AnsariH, LubanJ: The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.J. Virol.71(3), 2107–2113 (1997).
  • Dorfman T , WeimannA, BorsettiA, WalshCT, GottlingerHG: Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions.J. Virol.71(9), 7110–7113 (1997).
  • Billich A , HammerschmidF, PeichlPet al.: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein–cyclophilin A interactions.J. Virol.69(4), 2451–2461 (1995).
  • Rosenwirth B , BillichA, DatemaRet al.: Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog.Antimicrob. Agents Chemother.38(8), 1763–1772 (1994).
  • Franke EK , LubanJ: Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag–cyclophilin A interaction.Virology222(1), 279–282 (1996).
  • Dorfman T , GottlingerHG: The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.J. Virol.70(9), 5751–5757 (1996).
  • Bukovsky AA , WeimannA, AccolaMA, GottlingerHG: Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence.Proc. Natl Acad. Sci. USA94(20), 10943–10948 (1997).
  • Sharp PM , BailesE, RobertsonDL, GaoF, HahnBH: Origins and evolution of AIDS viruses.Biol. Bull.196(3), 338–342 (1999).
  • Aberham C , WeberS, PharesW: Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.J. Virol.70(6), 3536–3544 (1996).
  • Braaten D , AberhamC, FrankeEK, YinL, PharesW, LubanJ: Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A.J. Virol.70(8), 5170–5176 (1996).
  • Chatterji U , BobardtMD, StanfieldRet al.: Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.J. Biol. Chem.280(48), 40293–40300 (2005).
  • Braaten D , FrankeEK, LubanJ: Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.J. Virol.70(6), 3551–3560 (1996).
  • Vajdos FF , YooS, HouseweartM, SundquistWI, HillCP: Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein.Protein Sci.6(11), 2297–2307 (1997).
  • Gitti RK , LeeBM, WalkerJ, SummersMF, YooS, SundquistWI: Structure of the amino-terminal core domain of the HIV-1 capsid protein.Science273(5272), 231–235 (1996).
  • Wiegers K , RutterG, SchubertU, GrattingerM, KrausslichHG: Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid.Virology257(1), 261–274 (1999).
  • Grattinger M , HohenbergH, ThomasD, WilkT, MullerB, KrausslichHG: In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A.Virology257(1), 247–260 (1999).
  • Welker R , HohenbergH, TessmerU, HuckhagelC, KrausslichHG: Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1.J. Virol.74(3), 1168–1177 (2000).
  • Sherry B , ZybarthG, AlfanoMet al.: Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes.Proc. Natl Acad. Sci. USA95(4), 1758–1763 (1998).
  • Saphire AC , BobardtMD, GallayPA: Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.EMBO J.18(23), 6771–6785 (1999).
  • Pushkarsky T , ZybarthG, DubrovskyLet al.: CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.Proc. Natl Acad. Sci. USA98(11), 6360–6365 (2001).
  • Zhang YJ , HatziioannouTet al.: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection.J. Virol.76(12), 6332–6343 (2002).
  • Yin L , BraatenD, LubanJ: Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels.J. Virol.72(8), 6430–6436 (1998).
  • Ackerson B , ReyO, CanonJ, KrogstadP: Cells with high cyclophilin A content support replication of human immunodeficiency virus type 1 Gag mutants with decreased ability to incorporate cyclophilin A.J. Virol.72(1), 303–308 (1998).
  • Kootstra NA , MunkC, TonnuN, LandauNR, VermaIM: Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.Proc. Natl Acad. Sci. USA100(3), 1298–1303 (2003).
  • Sokolskaja E , SayahDM, LubanJ: Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.J. Virol.78(23), 12800–12808 (2004).
  • Hatziioannou T , Perez-CaballeroD, CowanS, BieniaszPD: Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.J. Virol.79(1), 176–183 (2005).
  • Goff SP : Retrovirus restriction factors.Mol. Cell16(6), 849–59 (2004).
  • Goff SP : Genetic control of retrovirus susceptibility in mammalian cells.Annu. Rev. Genet.38, 61–85 (2004).
  • Baumann JG : Intracellular restriction factors in mammalian cells – an ancient defense system finds a modern foe.Curr. HIV Res.4(2), 141–168 (2006).
  • Hatziioannou T , CowanS, GoffSP, BieniaszPD, TowersGJ: Restriction of multiple divergent retroviruses by Lv1 and Ref1.EMBO J.22(3), 385–394 (2003).
  • Besnier C , TakeuchiY, TowersG: Restriction of lentivirus in monkeys.Proc. Natl Acad. Sci. USA99(18), 11920–11925 (2002).
  • Cowan S , HatziioannouT, CunninghamT, MuesingMA, GottlingerHG, BieniaszPD: Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism.Proc. Natl Acad. Sci. USA99(18), 11914–11919 (2002).
  • Munk C , BrandtSM, LuceroG, LandauNR: A dominant block to HIV-1 replication at reverse transcription in simian cells.Proc. Natl Acad. Sci. USA99(21), 13843–13848 (2002).
  • Towers G , BockM, MartinS, TakeuchiY, StoyeJP, DanosO: A conserved mechanism of retro Virus Res. triction in mammals.Proc. Natl Acad. Sci. USA97(22), 12295–12299 (2000).
  • Towers G , CollinsM, TakeuchiY: Abrogation of Ref1 retrovirus restriction in human cells.J. Virol.76(5), 2548–2550 (2002).
  • Hatziioannou T , Perez-CaballeroD, YangA, CowanS, BieniaszPD: Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α.Proc. Natl Acad. Sci. USA101(29), 10774–10779 (2004).
  • Perron MJ , StremlauM, SongB, UlmW, MulliganRC, SodroskiJ: TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells.Proc. Natl Acad. Sci. USA101(32), 11827–11832 (2004).
  • Keckesova Z , YlinenLM, TowersGJ: The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities.Proc. Natl Acad. Sci. USA101(29), 10780–10785 (2004).
  • Yap MW , NisoleS, LynchC, StoyeJP: Trim5α protein restricts both HIV-1 and murine leukemia virus.Proc. Natl Acad. Sci. USA101(29), 10786–10791 (2004).
  • Reymond A , MeroniG, FantozziAet al.: The tripartite motif family identifies cell compartments.EMBO J.20(9), 2140–2151 (2001).
  • Stremlau M , PerronM, WelikalaS, SodroskiJ: Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction.J. Virol.79(5), 3139–3145 (2005).
  • Yap MW , NisoleS, StoyeJP: A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction.Curr. Biol.15(1), 73–78 (2005).
  • Sawyer SL , WuLI, EmermanM, MalikHS: Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain.Proc. Natl Acad. Sci. USA102(8), 2832–2837 (2005).
  • Perez-Caballero D , HatziioannouT, YangA, CowanS, BieniaszPD: Human tripartite motif 5α domains responsible for retrovirus restriction activity and specificity.J. Virol.79(14), 8969–8978 (2005).
  • Nakayama EE , MiyoshiH, NagaiY, ShiodaT: A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5α determines species-specific restriction of simian immunodeficiency virus SIVmac infection.J. Virol.79(14), 8870–8877 (2005).
  • Javanbakht H , Diaz-GrifferoF, StremlauM, SiZ, SodroskiJ: The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5α.J. Biol. Chem.280(29), 26933–26940 (2005).
  • Sayah DM , LubanJ: Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection.J. Virol.78(21), 12066–12070 (2004).
  • Berthoux L , SebastianS, SokolskajaE, LubanJ: Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells.Proc. Natl Acad. Sci. USA102(41), 14849–14853 (2005).
  • Keckesova Z , YlinenLM, TowersGJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5α antiviral activity.J. Virol.80(10), 4683–4690 (2006).
  • Hofmann W , SchubertD, LaBonteJet al.: Species-specific, postentry barriers to primate immunodeficiency virus infection.J. Virol.73(12), 10020–10028 (1999).
  • Nisole S , LynchC, StoyeJP, YapMW: A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1.Proc. Natl Acad. Sci. USA101(36), 13324–13328 (2004).
  • Sokolskaja E , BerthouxL, LubanJ: Cyclophilin A and TRIM5α independently regulate human immunodeficiency virus type 1 infectivity in human cells.J. Virol.80(6), 2855–2862 (2006).
  • Owens CM , SongB, PerronMJ, YangPC, StremlauM, SodroskiJ: Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid.J. Virol.78(10), 5423–5437 (2004).
  • Hatziioannou T , CowanS, Von SchwedlerUK, SundquistWI, BieniaszPD: Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid.J. Virol.78(11), 6005–6012 (2004).
  • Stremlau M , SongB, JavanbakhtH, PerronM, SodroskiJ: Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5α restriction of HIV-1.Virology351, 112–120 (2006).
  • Bosco DA , EisenmesserEZ, PochapskyS, SundquistWI, KernD: Catalysis ofcis/trans isomerization in native HIV-1 capsid by human cyclophilin A.Proc. Natl Acad. Sci. USA99(8), 5247–5252 (2002).
  • Eisenmesser EZ , MilletO, LabeikovskyWet al.: Intrinsic dynamics of an enzyme underlies catalysis.Nature438(7064), 117–121 (2005).
  • Howard BR , VajdosFF, LiS, SundquistWI, HillCP: Structural insights into the catalytic mechanism of cyclophilin A.Nat. Struct. Biol.10(6), 475–481 (2003).
  • Li L , LiHS, PauzaCD, BukrinskyM, ZhaoRY: Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions.Cell Res.15(11–12), 923–934 (2005).
  • Le Rouzic E , BenichouS: The Vpr protein from HIV-1: distinct roles along the viral life cycle.RetroVirology2(1), 11 (2005).
  • Gibbs JS , LacknerAA, LangSMet al.: Progression to AIDS in the absence of a gene for vpr or vpx.J. Virol.69(4), 2378–2383 (1995).
  • Lang SM , WeegerM, Stahl-HennigCet al.: Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.J. Virol.67(2), 902–912 (1993).
  • Bruns K , FossenT, WrayV, HenkleinP, TessmerU, SchubertU: Structural characterization of the HIV-1 Vpr N terminus: evidence of cisl trans-proline isomerism.J. Biol. Chem.278(44), 43188–43201 (2003).
  • Zander K , ShermanMP, TessmerUet al.: Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression.J. Biol. Chem.278(44), 43202–43213 (2003).
  • Ardon O , ZimmermanES, AndersenJL, DehartJL, BlackettJ, PlanellesV: Induction of G2 arrest and binding to cyclophilin a are independent phenotypes of human immunodeficiency virus type 1 vpr.J. Virol.80(8), 3694–3700 (2006).
  • Colgan J , AsmalM, YuB, LubanJ: Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine.J. Immunol.174(10), 6030–6038 (2005).
  • Cron RQ : HIV-1, NFAT, and cyclosporin: immunosuppression for the immunosuppressed?DNA Cell Biol.20(12), 761–7 (2001).
  • Argyropoulos C , MouzakiA: Immunosuppressive drugs in HIV disease.Curr. Top. Med. Chem.6(16), 1769–1789 (2006).
  • Martin LN , Murphey-CorbM, MackPet al.: Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys.J. Infect. Dis.176(2), 374–383 (1997).
  • Schindler M , MunchJ, KutschOet al.: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.Cell125(6), 1055–1067 (2006).
  • Andrieu JM , EvenP, VenetAet al.: Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.Clin. Immunol. Immunopathol.47(2), 181–198 (1988).
  • Levy R , JaisJP, TouraniJM, EvenP, AndrieuJM: Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A.Adv. Exp. Med. Biol.374, 229–234 (1995).
  • Phillips A , WainbergMA, CoatesRet al.: Cyclosporine-induced deterioration in patients with AIDS.CMAJ140(12), 1456–1460 (1989).
  • Clavel F , HanceAJ: HIV drug resistance.N. Engl. J. Med.350(10), 1023–1035 (2004).
  • Ingulli E , TejaniA, FikrigS, NicastriA, ChenCK, PomrantzA: Nephrotic syndrome associated with acquired immunodeficiency syndrome in children.J. Pediatr.119(5), 710–716 (1991).
  • Tourne L , DurezP, VanVooren JPet al.: Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine.J. Am. Acad. Dermatol.37(3 Pt 1), 501–502 (1997).
  • Caselli D , MaccabruniA, BeluffiG, MinoliL: Cyclosporine for rectoperineal fistula in a human immunodeficiency virus-infected child.J. Pediatr. Gastroenterol. Nutr.28(3), 333–335 (1999).
  • Griffiths JK : Successful long-term use of cyclosporin A in HIV-induced pityriasis lichenoides chronica.J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.18(4), 396–397 (1998).
  • Calabrese LH , LedermanMM, SpritzlerJet al.: Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.J. Acquir. Immune Defic. Syndr.29(4), 356–362 (2002).
  • Rizzardi GP , HarariA, CapiluppiBet al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.J. Clin. Invest.109(5), 681–688 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.